The primary goal of this study is to improve the overall efficacy of cognitive processing therapy-cognitive-only version (CPT-C) in a sample of 130 active-duty service members through a variable length treatment.
The primary goal of this study is to improve the overall efficacy of cognitive processing therapy-cognitive-only version (CPT-C) in a sample of 130 active-duty service members through a variable length treatment. The study seeks to determine if some service members would benefit from a longer or shorter dose of treatment (4-24 sessions), and to identify which individuals are likely to require more, less, or the standard number of treatment sessions to reach good end-state functioning. Predictors of length of therapy and treatment outcome will be examined. Specifically, we will evaluate factors related to internalizing/externalizing traits, cognitive flexibility, inability to inhibit dysfunctional cognitions, and readiness to change as they are related to the number of treatment sessions required to treat patients to the point of good end-state functioning. Additional outcomes including alcohol use, psychosocial functioning, physical health, and sleep also will be evaluated.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
TREATMENT
Masking
NONE
Enrollment
130
Cognitive Processing Therapy-Cognitive Only (CPT-C) is an evidence-based form of Cognitive Behavioral Therapy (CBT) used to treat PTSD. CPT is a manualized program that focuses on challenging beliefs and assumptions related to the trauma, oneself, and the world. Individual sessions will be conducted twice weekly for 4-24 sessions; each session is 60 minutes.
Carl R Darnall Army Medical Center
Fort Hood, Texas, United States
Change from baseline in PTSD symptoms as measured by thePosttraumatic Stress Disorder Checklist-5 (PCL-5)
PCL-5 measures symptoms of posttraumatic stress disorder in response to a specific stressor.
Time frame: Pretreatment, weekly during treatment, 4 weeks, 12 weeks, and 24 weeks posttreatment
Change from baseline in PTSD symptoms as measured by the Clinician Administered PTSD Scale (CAPS-5)
is an updated version of the gold standard CAPS designed to assess the criteria for PTSD as defined by the DSM-5
Time frame: Pretreatment, weekly during treatment, 4 weeks, 12 weeks, and 24 weeks posttreatment
Change from baseline in depressive symptoms as measured by the Patient Health Questionnaire-9
The PHQ-9 is a widely used and well-validated instrument for measuring the severity of depressive symptoms (Kroenke, Spitzer, \& Williams, 2001). It consists of 9 items that assess both affective and somatic symptoms related to depression and depressive disorders; these 9 items correspond to the diagnostic criteria for DSM MDD. Respondents rate the frequency with which they have been bothered by depressive symptoms within the past two weeks on a scale ranging from 0 ("not at all") to 3 ("nearly every day"). Scores on all items are summed to obtain a total severity score.
Time frame: Pretreatment, weekly during treatment, 4 weeks, 12 weeks, and 24 weeks posttreatment
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.